Skip to main content

RT @uptoTate: DANBIO registry plenary Abs 1112 finds 1 yr retention following a mandatory nationwide infliximab biosimil

Nov 13, 2022 12:07 pm
Social Author Name
Dr. Rachel Tate
Tweet Content
DANBIO registry plenary Abs 1112 finds 1 yr retention following a mandatory nationwide infliximab biosimilar-to-biosimilar switch was high. Retention higher in originator-experienced and in pts w/ low disease activity. #ACR22 @RheumNow https://t.co/ZAV2dcVzXl https://t.co/Kti2bZ1pkZ
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×